EBE, EFPIA and IFPMA have today launched a position paper entitled “Considerations for physicians on switching decisions regarding biosimilars”.
Switching describes a physician’s decision to exchange one product that a patient receives for another. With the introduction of biosimilars, physicians may be encouraged to switch patients from an original biologic (reference product) to any of its biosimilars (or vice versa) in order to reduce costs. The considerations take into account the unique characteristics of...
Read morePharma industry launches call for coalition of countries to pilot new incentives for antibiotic R&D
16 November, Geneva – The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) draws attention on the urgent need for governments across the world to put in place a suite of incentives to reinvigorate the antimicrobial pipeline. Adoption by governments of sustainable and substantial measures to fund or reward research inputs and outputs incentives must...
Read moreAMR life science industry 2020 report: Successes and setbacks in fighting superbugs
AMR Industry Alliance reports breakthroughs in the responsible manufacturing of antibiotics and positive steps to improve how patients access and use antibiotics. But its report also highlights concerning levels of research and development (R&D) investment. Alliance records US$6bn annual investment (in 2018) in antimicrobial resistance (AMR)-relevant R&D. Concerning shortfall is in late stage R&D investment...
Read moreNew AMR Action Fund steps in to save collapsing antibiotic pipeline with pharmaceutical industry investment of US$1 billion
New AMR Action Fund steps in to save collapsing antibiotic pipeline with pharmaceutical industry investment of US$1 billion. This partnership aims to bring 2 to 4 new antibiotics to patients by the end of the decade and facilitate needed long-term policy solutions.
Read more20 leading research, medical and pharmaceutical organizations call on G7 to step up action to strengthen the R&D antibiotic pipeline
November 17, 2021, Berlin – Ahead of the “World Antimicrobial Awareness Week” (November 18-24) 20 national and international organizations from academia, healthcare and the pharmaceutical industry appealed today to G7 governments to step up efforts to tackle the problem of growing antibiotic resistance. In a joint statement, they stress that only an approach involving both the...
Read moreDelivering equitable access in pandemics: Biopharmaceutical industry commitments
In response to the threat of future global pandemics, the biopharmaceutical industry developed a set of commitments for equitable access to essential medical countermeasures in future pandemics.
Read moreIFPMA and WADA Joint Declaration on Cooperation in the Fight against Doping in Sport
Read moreRegulatory Conferences
Read moreAnn-Lise Mikolajczak
Ann-Lise works toward improving access to medicines, health products, and quality care in low-and middle-income countries, with a current focus on NCDs/oncology and rare diseases. She is also playing a leading role on policies at the nexus of climate change and health. She supports advocacy and policy development on these topics as well as strategic engagement...
Read more
Sérgio Cavalheiro Filho
Sérgio works with different IFPMA regulatory workstreams in the development of technical policy documents and implementation of related advocacy activities for regulatory system strengthening, manufacturing quality, and regulatory reliance. He also spearheaded IFPMA’s contribution toward the establishment of the Fight the Fakes Alliance. Before joining IFPMA, Sérgio worked on late-stage drug formulation and development, and...
Read more